Long-term follow-up from a Phase II trial of olutasidenib in IDH1-mutated AML

Jorge Cortes, MD, Georgia Cancer Center, Augusta, GA, discusses the long-term follow-up results from the Phase II trial of olutasidenib in IDH1-mutated acute myeloid leukemia (AML). He highlights a 35% response rate with significant durability of response, lasting more than two years. He notes no new adverse events or late toxicities, emphasizing that more than 50% of patients continue on therapy for three to four years, maintaining their response. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.